Fig. 1From: Clinical and histopathological analyses of VEGF receptors peptide vaccine in patients with primary glioblastoma - a case seriesThe Protocol for this clinical trial. The scheme of the Protocol for this clinical trial is shown. VEGFR1 and R2 peptide were injected eight times every week and then six times monthly (a total of 14 times). Vaccination was synchronized with adjuvant TMZBack to article page